CELC
Price
$9.38
Change
+$0.09 (+0.97%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
347.53M
46 days until earnings call
CRNX
Price
$31.35
Change
+$0.73 (+2.38%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
2.92B
35 days until earnings call
Ad is loading...

CELC vs CRNX

Header iconCELC vs CRNX Comparison
Open Charts CELC vs CRNXBanner chart's image
Celcuity
Price$9.38
Change+$0.09 (+0.97%)
Volume$6.02K
Capitalization347.53M
Crinetics Pharmaceuticals
Price$31.35
Change+$0.73 (+2.38%)
Volume$37.17K
Capitalization2.92B
CELC vs CRNX Comparison Chart
Loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CELC vs. CRNX commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CELC is a Hold and CRNX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (CELC: $9.29 vs. CRNX: $30.62)
Brand notoriety: CELC and CRNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CELC: 434% vs. CRNX: 224%
Market capitalization -- CELC: $347.53M vs. CRNX: $2.92B
CELC [@Biotechnology] is valued at $347.53M. CRNX’s [@Biotechnology] market capitalization is $2.92B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CELC’s FA Score shows that 0 FA rating(s) are green whileCRNX’s FA Score has 0 green FA rating(s).

  • CELC’s FA Score: 0 green, 5 red.
  • CRNX’s FA Score: 0 green, 5 red.
According to our system of comparison, CELC is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CELC’s TA Score shows that 3 TA indicator(s) are bullish while CRNX’s TA Score has 4 bullish TA indicator(s).

  • CELC’s TA Score: 3 bullish, 5 bearish.
  • CRNX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CRNX is a better buy in the short-term than CELC.

Price Growth

CELC (@Biotechnology) experienced а -11.61% price change this week, while CRNX (@Biotechnology) price change was -12.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.27%. For the same industry, the average monthly price growth was -7.37%, and the average quarterly price growth was -12.08%.

Reported Earning Dates

CELC is expected to report earnings on May 19, 2025.

CRNX is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-5.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($2.92B) has a higher market cap than CELC($348M). CELC YTD gains are higher at: -29.030 vs. CRNX (-40.113). CELC has higher annual earnings (EBITDA): -85.45M vs. CRNX (-336.07M). CRNX has more cash in the bank: 1.35B vs. CELC (264M). CRNX has less debt than CELC: CRNX (51.7M) vs CELC (97.2M). CRNX has higher revenues than CELC: CRNX (1.04M) vs CELC (0).
CELCCRNXCELC / CRNX
Capitalization348M2.92B12%
EBITDA-85.45M-336.07M25%
Gain YTD-29.030-40.11372%
P/E RatioN/AN/A-
Revenue01.04M-
Total Cash264M1.35B19%
Total Debt97.2M51.7M188%
FUNDAMENTALS RATINGS
CELC vs CRNX: Fundamental Ratings
CELC
CRNX
OUTLOOK RATING
1..100
7856
VALUATION
overvalued / fair valued / undervalued
1..100
38
Fair valued
90
Overvalued
PROFIT vs RISK RATING
1..100
9065
SMR RATING
1..100
9895
PRICE GROWTH RATING
1..100
6485
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CELC's Valuation (38) in the Miscellaneous Commercial Services industry is somewhat better than the same rating for CRNX (90) in the Pharmaceuticals Major industry. This means that CELC’s stock grew somewhat faster than CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (65) in the Pharmaceuticals Major industry is in the same range as CELC (90) in the Miscellaneous Commercial Services industry. This means that CRNX’s stock grew similarly to CELC’s over the last 12 months.

CRNX's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as CELC (98) in the Miscellaneous Commercial Services industry. This means that CRNX’s stock grew similarly to CELC’s over the last 12 months.

CELC's Price Growth Rating (64) in the Miscellaneous Commercial Services industry is in the same range as CRNX (85) in the Pharmaceuticals Major industry. This means that CELC’s stock grew similarly to CRNX’s over the last 12 months.

CELC's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that CELC’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CELCCRNX
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 10 days ago
83%
Bullish Trend 10 days ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
77%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
CELC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GBCCX14.44N/A
N/A
Gabelli Dividend Growth C
FSPHX26.97N/A
N/A
Fidelity Select Health Care
ADGCX14.52N/A
N/A
AB Core Opportunities C
GCVAX23.19N/A
N/A
Goldman Sachs Large Cp Val Insghts A
JSGRX24.62N/A
N/A
JHancock U.S. Growth R2

CELC and

Correlation & Price change

A.I.dvisor indicates that over the last year, CELC has been loosely correlated with PRME. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if CELC jumps, then PRME could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CELC
1D Price
Change %
CELC100%
-8.11%
PRME - CELC
44%
Loosely correlated
-10.30%
ABOS - CELC
43%
Loosely correlated
-2.27%
CRNX - CELC
43%
Loosely correlated
-8.71%
CLDX - CELC
43%
Loosely correlated
-7.16%
VTGN - CELC
41%
Loosely correlated
-6.40%
More

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with ELVN. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then ELVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
-8.71%
ELVN - CRNX
51%
Loosely correlated
-4.07%
TRDA - CRNX
50%
Loosely correlated
-3.10%
INZY - CRNX
48%
Loosely correlated
-4.40%
IDYA - CRNX
48%
Loosely correlated
-9.83%
IGMS - CRNX
47%
Loosely correlated
N/A
More